Retatrutide Dose-Response Findings: What Trial Arms Reported

Disclosure: Peptide Bio Index is affiliated with SourcePoint Research and may earn from qualifying purchases or affiliate links.

This evidence deep dive summarizes the retatrutide dose-ranging trial arms and the dose–response data explicitly reported in the reviewed literature, focusing on the Phase 2 randomized trial and subsequent syntheses that reference the 8 mg and 12 mg dose levels (primary human efficacy and safety data are drawn from the phase 2 NEJM report, with context from later systematic reviews and network meta-analysis) (S2, S8, S3).

Phase 2 randomized, double-blind trial: design and explicit trial arms

The pivotal Phase 2 randomized, double-blind, placebo-controlled trial (n = 338 adults) tested multiple fixed-weekly retatrutide dose groups and included explicit starting-dose variations; participants had BMI ≥30 or BMI 27–<30 plus at least one weight-related condition. The trial randomly assigned participants in a 2:1:1:1:1:2:2 ratio to receive subcutaneous retatrutide (1 mg; 4 mg with initial dose 2 mg; 4 mg with initial dose 4 mg; 8 mg with initial dose 2 mg; 8 mg with initial dose 4 mg; 12 mg with initial dose 2 mg) or placebo once weekly for 48 weeks, with the primary end point specified as percentage change in body weight from baseline to 24 weeks (S2). ^[S2]

Reported dose groups and how they were analyzed

The Phase 2 report presents both single-dose groups (1 mg and 12 mg) and several dose levels with alternate starting-dose regimens that were pooled for some analyses (reported as combined 4-mg and combined 8-mg groups). The trial therefore reports outcomes for 1 mg, combined 4 mg, combined 8 mg, and 12 mg dose cohorts versus placebo, reflecting the prespecified grouping and analysis approach in the publication (S2). ^[S2]

Dose–response efficacy outcomes reported at 24 and 48 weeks

The Phase 2 trial reported a clear dose–response pattern for percent weight change: at 24 weeks the least-squares mean percent changes were −7.2% (1 mg), −12.9% (combined 4 mg), −17.3% (combined 8 mg), and −17.5% (12 mg), versus −1.6% with placebo; at 48 weeks the corresponding least-squares mean percent changes were −8.7% (1 mg), −17.1% (combined 4 mg), −22.8% (combined 8 mg), and −24.2% (12 mg) versus −2.1% with placebo. Categorical responses at 48 weeks (≥5%, ≥10%, ≥15% weight loss) were reported by dose group (for example, 12 mg: 100% ≥5%, 93% ≥10%, 83% ≥15%; 8 mg: 100% ≥5%, 91% ≥10%, 75% ≥15%; 4 mg: 92% ≥5%, 75% ≥10%, 60% ≥15%; placebo: 27% ≥5%, 9% ≥10%, 2% ≥15%) (S2). These Phase 2 findings are reflected in subsequent systematic reviews and network meta-analyses that list retatrutide 8 mg and 12 mg among the most efficacious regimens for percent weight reduction in trial data synthesized to August 2024 (S8, S3). ^{[S2] [S8] [S3]}

Dose-related safety signals and starting-dose mitigation

The Phase 2 publication reports that gastrointestinal adverse events were the most common events, were dose-related in frequency and severity, and were partially mitigated when a lower starting dose (2 mg) was used instead of a higher initial step; dose-dependent increases in heart rate were observed to peak at 24 weeks and decline thereafter. Systematic reviews of RCTs also summarize that gastrointestinal adverse events are the predominant safety findings across GLP-1–based co-agonists and triple agonists evaluated for weight loss (S2, S8). ^{[S2] [S8]}

Phase 3 TRIUMPH program and broader development context

A Phase 3 registrational program (TRIUMPH) has been described in the literature as a set of four randomized, double-blind, multicenter Phase 3 trials that will evaluate weekly subcutaneous retatrutide versus placebo across weight-management and related comorbidity cohorts (obstructive sleep apnea, knee osteoarthritis, and cardiovascular disease) in over 5,800 participants; the TRIUMPH manuscripts describe endpoints and a basket-trial design but the provided excerpt does not report specific Phase 3 dosing regimens (S6). Reviews and commentary place retatrutide in the class of triple-receptor agonists (GIP/GLP-1/glucagon), emphasizing its development trajectory from Phase 2 efficacy findings toward larger registrational programs (S1, S4). ^{[S6] [S1] [S4]}

Reported study-design details from cited sources

The following table summarizes protocol details reported in cited studies. These details are provided as literature context only and are not recommendations or instructions.

Limitations and research gaps

• Most detailed human dose–response data available in the reviewed set derive from a single Phase 2 randomized trial (S2); broader confirmation awaits completed Phase 3 trials (S6).
• The Phase 2 publication reports pooled 'combined' groups for some dose levels (combined 4 mg, combined 8 mg) due to starting-dose variants; this complicates interpretation of effects attributable to a single fixed titration scheme (S2).
• Systematic reviews and network meta-analyses synthesize multiple trials and populations, but heterogeneity in trial designs and populations (including diabetes status) limits direct within-trial dose comparisons and head-to-head inferences (S3, S8).
• Phase 3 TRIUMPH design manuscripts describe the program and endpoints but the provided excerpt does not include Phase 3 dosing regimens or on-treatment durations for those trials (S6).

Documentation checklist

• Primary Phase 2 randomized, double-blind, placebo-controlled trial in The New England Journal of Medicine (S2) reports the detailed dose arms and key 24- and 48-week outcomes.
• Phase 2 trial included multiple starting-dose strategies (pooled as 'combined' groups for analysis) — interpret pooled arms as reported trial-group constructs (S2).
• Systematic reviews and a network meta-analysis list retatrutide 8 mg and 12 mg as the principal doses evaluated across RCTs and estimate large mean weight-loss effects (S3, S8).
• Phase 3 TRIUMPH registrational program is described in a trial-design manuscript; specific phase-3 dosing regimens were not reported in the provided excerpt (S6).
• Gastrointestinal adverse events were dose-related in the phase 2 trial and were partially mitigated by using a lower starting dose; heart-rate increases were dose-dependent and peaked at 24 weeks (S2, S8).

Related research supplies

• Temperature-monitored storage boxes and logs for investigational product accountability
• Labeling templates for blinded study drug vials (placebo and active) and randomization codes
• Clinical trial refrigerator/freezer inventory sheets and temperature alarm systems
• Study drug dispensing log templates and electronic case-report form (eCRF) sample fields
• Non-hazardous surface disinfectant wipes and lint-free storage containers for protocol materials

Sources and references

1. [S1] Son JW, le Roux CW, Blüher M, Nauck MA, Lim S. Novel GLP-1-based Medications for Type 2 Diabetes and Obesity.. Endocrine reviews. 2026. PMID: 41054801. DOI: 10.1210/endrev/bnaf036
2. [S2] Jastreboff AM, Kaplan LM, Frías JP, Wu Q, Du Y, Gurbuz S. Triple-Hormone-Receptor Agonist Retatrutide for Obesity – A Phase 2 Trial.. The New England journal of medicine. 2023. PMID: 37366315. DOI: 10.1056/NEJMoa2301972
3. [S3] Xie Z, Zheng G, Liang Z, Li M, Deng W, Cao W. Seven glucagon-like peptide-1 receptor agonists and polyagonists for weight loss in patients with obesity or overweight: an updated systematic review and network meta-analysis of randomized controlled trials.. Metabolism: clinical and experimental. 2024. PMID: 39305981. DOI: 10.1016/j.metabol.2024.156038
4. [S4] Katsi V, Koutsopoulos G, Fragoulis C, Dimitriadis K, Tsioufis K. Retatrutide-A Game Changer in Obesity Pharmacotherapy.. Biomolecules. 2025. PMID: 40563436. DOI: 10.3390/biom15060796
5. [S5] Drucker DJ. Efficacy and Safety of GLP-1 Medicines for Type 2 Diabetes and Obesity.. Diabetes care. 2024. PMID: 38843460. DOI: 10.2337/dci24-0003
6. [S6] Giblin K, Kaplan LM, Somers VK, Le Roux CW, Hunter DJ, Wu Q. Retatrutide for the treatment of obesity, obstructive sleep apnea and knee osteoarthritis: Rationale and design of the TRIUMPH registrational clinical trials.. Diabetes, obesity & metabolism. 2026. PMID: 41090431. DOI: 10.1111/dom.70209
7. [S7] Rubio-Herrera MA, Mera-Carreiro S. Weight management treatment in obesity.. Medicina clinica. 2025. PMID: 40865172. DOI: 10.1016/j.medcli.2025.107152
8. [S8] Moiz A, Filion KB, Toutounchi H, Tsoukas MA, Yu OHY, Peters TM. Efficacy and Safety of Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss Among Adults Without Diabetes : A Systematic Review of Randomized Controlled Trials.. Annals of internal medicine. 2025. PMID: 39761578. DOI: 10.7326/ANNALS-24-01590

Peptide Bio Index is affiliated with SourcePoint Research. Articles may link to SourcePointResearch.com and third-party affiliate products. As an Amazon Associate, Peptide Bio Index earns from qualifying purchases. Content is educational and research-literature focused only and is not medical advice, dosing guidance, or a personal-use recommendation.